CORDIS
EU research results

CORDIS

English EN

Towards Early diagnosis and biomarker validation in Arthritis Management

Objective

An ideal intervention in a chronic inflammatory disease such as Rheumatoid Arthritis (RA) would be a preventive one. In order to develop preventive strategies and therapies two key developments need to occur: (1) Biomarkers need to be identified that can be used to predict an individual’s risk of developing RA. (2) Modifiable disease mechanisms need to be identified and characterized in the early phases of disease. The key objective of the TEAM consortium is to specifically identify diagnostic biomarkers and disease mechanisms operating during the transition from health to rheumatoid arthritis. Our consortium will achieve this by developing a collaborative, integrated programme of work that links researchers with key SMEs involved in biomarker development to produce a “personalized predictive bioprofile” for patients destined to develop RA. The Euro-TEAM consortium will deliver a step change in the development of biomarkers and diagnostic kits that are timely, strategically important for European SMEs, and based on a disease (RA) in which concrete genetic and environmental risk factors have already been established. Firstly, it will directly compare biomarkers in the preclinical phases of disease with established markers in the clinical phases. Secondly, it will look beyond the synovium interrogating lymphoid, lung and periodontal tissue in a first-in-class approach to measuring systemic changes in the earliest phases of disease. Thirdly, it will place great emphasis on understanding why synovial inflammation resolves in some individuals and develop biomarkers of this “reverse” phase. Fourthly, it will explore a key cell type (stromal cells) that has been almost completely ignored in current biomarker studies. Finally, it will directly involve patients and other specialists, particularly from the fields of genetics, ethics and patient and public involvement in helping to visualize and communicate risk following a positive biomarker test.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE UNIVERSITY OF BIRMINGHAM

Address

Edgbaston
B15 2tt Birmingham

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 245 220

Administrative Contact

Erica Conway (Ms.)

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 357 800

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 417 600

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 358 040

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 351 970

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 252 800

UNIVERSITY OF LEEDS

United Kingdom

EU Contribution

€ 218 000

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 218 000

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 158 000

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 158 000

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 549 999

KUNGLIGA TEKNISKA HOEGSKOLAN

Sweden

EU Contribution

€ 210 200

Arthrogen BV

Netherlands

EU Contribution

€ 236 295

ORGENTEC DIAGNOSTIKA GMBH

Germany

EU Contribution

€ 347 850

ISLENSK ERFDAGREINING EHF

Iceland

EU Contribution

€ 518 800

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 178 800

Project information

Grant agreement ID: 305549

Status

Closed project

  • Start date

    1 November 2012

  • End date

    31 October 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 609 029,60

  • EU contribution

    € 5 777 374

Coordinated by:

THE UNIVERSITY OF BIRMINGHAM

United Kingdom